{
  "report_rows": [
    {
      "kpi": "Total organic revenue growth",
      "prediction": "MISS",
      "answer": "pred ~0.6% vs. cons 0.9%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.10 vs. cons $1.08",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.73B vs. cons $1.72B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Consolidated organic revenue growth",
      "prediction": "LOWER",
      "answer": "guide ~2.0% vs. cons 2.3% (2H 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Accession adjusted EBITDAC margin",
      "prediction": "UNCHANGED",
      "answer": "guide ~35.0% vs. cons 35.0% (FY 2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Accession EBITDA synergies",
      "prediction": "UNCHANGED",
      "answer": "guide ~$35M vs. cons $35M (FY 2026)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": -3.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -5.2,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "An EPS beat of roughly $1.10 versus $1.08 is unlikely to offset organic growth of about 0.6% versus 0.9% and softer 2H growth commentary of roughly 2.0% versus 2.3%; FY2026 EPS estimates could drift toward ~$4.48 from ~$4.52 as weaker out-period organic growth outweighs contingents and expense control.",
  "day5_confidence": "MEDIUM"
}